Processa Pharmaceuticals, Inc. Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share
Processa Pharmaceuticals, Inc. (PCSA) reported Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share of $0.00 per share for the 3-month period ending 2017-09-30, per its 10-Q filed 2017-11-20.
Discontinued › Income Statement › Net Income
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare · last filed 2017-11-20
- Processa Pharmaceuticals, Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for the quarter ending 2017-09-30 was $0.00.
- Processa Pharmaceuticals, Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for the quarter ending 2017-06-30 was $0.00.
- Processa Pharmaceuticals, Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for the quarter ending 2017-03-31 was $0.00.
- Processa Pharmaceuticals, Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for the quarter ending 2016-09-30 was $0.00.
- Processa Pharmaceuticals, Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for fiscal 2016 was $0.00.
- Processa Pharmaceuticals, Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for fiscal 2015 was -$0.03.
- Processa Pharmaceuticals, Inc. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic and diluted share for fiscal 2014 was -$0.09.
| Period end | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share 3 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share 6 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share 9 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share 12 month |
|---|---|---|---|---|
| 2017-09-30 | $0.00 10-Q · filed 2017-11-20 | $0.00 10-Q · filed 2017-11-20 | ||
| 2017-06-30 | $0.00 10-Q · filed 2017-10-04 | $0.00 10-Q · filed 2017-10-04 | ||
| 2017-03-31 | $0.00 10-Q · filed 2017-10-04 | |||
| 2016-12-31 | $0.00 10-K · filed 2017-09-25 | |||
| 2016-09-30 | $0.00 10-Q · filed 2017-11-20 | $0.00 10-Q · filed 2017-11-20 | ||
| 2016-06-30 | $0.00 10-Q · filed 2017-10-04 | $0.00 10-Q · filed 2017-10-04 | ||
| 2016-03-31 | $0.00 10-Q · filed 2017-10-04 | |||
| 2015-12-31 | -$0.03 10-K · filed 2017-09-25 | |||
| 2015-09-30 | -$0.01 10-Q · filed 2017-09-08 | -$0.03 10-Q · filed 2017-09-08 | ||
| 2015-06-30 | -$0.01 10-Q · filed 2017-08-30 | -$0.02 10-Q · filed 2017-08-30 | ||
| 2015-03-31 | -$0.01 10-Q · filed 2017-08-07 | |||
| 2014-12-31 | -$0.09 10-K · filed 2017-06-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |